AU757649B2 - Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities - Google Patents

Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Download PDF

Info

Publication number
AU757649B2
AU757649B2 AU64962/99A AU6496299A AU757649B2 AU 757649 B2 AU757649 B2 AU 757649B2 AU 64962/99 A AU64962/99 A AU 64962/99A AU 6496299 A AU6496299 A AU 6496299A AU 757649 B2 AU757649 B2 AU 757649B2
Authority
AU
Australia
Prior art keywords
tumor
squalamine
treatment
treatment procedure
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64962/99A
Other languages
English (en)
Other versions
AU6496299A (en
Inventor
Mitchell H. Sokoloff
Jon Williams
Michael Zasloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Publication of AU6496299A publication Critical patent/AU6496299A/en
Assigned to GENSERA CORPORATION reassignment GENSERA CORPORATION Amend patent request/document other than specification (104) Assignors: MAGAININ PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU757649B2 publication Critical patent/AU757649B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU64962/99A 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities Ceased AU757649B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15072498A 1998-09-10 1998-09-10
US09/150724 1998-09-10
PCT/US1999/020645 WO2000015176A2 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Publications (2)

Publication Number Publication Date
AU6496299A AU6496299A (en) 2000-04-03
AU757649B2 true AU757649B2 (en) 2003-02-27

Family

ID=22535747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64962/99A Ceased AU757649B2 (en) 1998-09-10 1999-09-10 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities

Country Status (5)

Country Link
EP (1) EP1119361A4 (https=)
JP (1) JP2002524481A (https=)
AU (1) AU757649B2 (https=)
CA (1) CA2343133A1 (https=)
WO (1) WO2000015176A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
JPS6133121A (ja) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk 制癌剤
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
DE19606355A1 (de) * 1996-02-12 1997-08-14 Schering Ag Kontrazeptive Freisetzungssysteme mit antiviraler und/oder antibakterieller Wirkung
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.

Also Published As

Publication number Publication date
WO2000015176A2 (en) 2000-03-23
WO2000015176A3 (en) 2000-07-20
EP1119361A4 (en) 2006-10-04
CA2343133A1 (en) 2000-03-23
EP1119361A2 (en) 2001-08-01
AU6496299A (en) 2000-04-03
JP2002524481A (ja) 2002-08-06

Similar Documents

Publication Publication Date Title
US6596712B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AU735884B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents
AU633954B2 (en) Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
EA016653B1 (ru) Способы и композиции для ингибирования ангиогенеза
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
CN105792845A (zh) 使用低氧活化的前药与紫杉烷类化合物的组合治疗胰腺癌
US20120214758A1 (en) Tyrosine kinase receptor antagonists and methods of treatment for pancreatic cancer
Li et al. Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor
US10022421B2 (en) Treatment of primary and metastatic carcinoma
Patel et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors
Xue et al. Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma
AU2005308539A1 (en) Method and composition for enhancing anti-angiogenic therapy
Robertson et al. A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
AU757649B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AU2019352068B2 (en) Combinations with a C-19 steroid for treating cancers
Wolf et al. Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury
US20060052457A1 (en) Use of ppar alpha agonists for the treatment of vascular and renal diseases
JP2002524481A5 (https=)
Williams Squalamine: A new angiostatic steroid
JP2010503689A (ja) 甲状腺刺激ホルモン（ｔｓｈ）の治療的投与のための配合物
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
Yuan et al. Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV
Rodriguez et al. beková, K. Řeřábek, J. Grimová, and J. Svobodová.
Allison Delivery of oseltamivir phosphate and gemcibatine from implantable poly (D, L-lactic-co-glycolic acid) cylinders for the treatment of pancreatic cancer

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: GENSERA CORPORATION

Free format text: FORMER NAME: MAGAININ PHARMACEUTICALS, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION NUMBER 64962/99 SHOULD READ: GENAERA CORPORATION

FGA Letters patent sealed or granted (standard patent)